Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma

N Worel; H Greinix; J Ackermann; H Kaufmann; E Urbauer; P Höcker; H Gisslinger; K Lechner; P Kalhs; J Drach

doi:10.1007/s002770100296

Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma

Ann Hematol. 2001 Jun;80(6):345-8. doi: 10.1007/s002770100296.

Authors

N Worel¹, H Greinix, J Ackermann, H Kaufmann, E Urbauer, P Höcker, H Gisslinger, K Lechner, P Kalhs, J Drach

Affiliation

¹ Division of Clinical Oncology, University of Vienna, Austria.

PMID: 11475148
DOI: 10.1007/s002770100296

Abstract

Interphase cytogenetic analysis of chromosome 13q14 was performed in 28 patients with multiple myeloma (MM) receiving high-dose therapy followed by autologous (n=24) or allogeneic (n=4) stem cell support. Eleven (39%) patients were found to have a deletion of chromosome 13q14. Response rates to high-dose therapy were independent of the chromosome 13 status, but patients with a deletion of 13q14 had a significantly shorter progression-free (p=0.001) and overall survival (p=0.012) than patients with normal chromosome 13q14. Our results indicate that high-dose therapy appears promising in patients with normal chromosome 13, whereas in patients with a deletion of 13q14 innovative therapeutic concepts are warranted.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Actuarial Analysis
Adult
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Chromosomes, Human, Pair 13 / genetics*
Disease-Free Survival
Female
Gene Deletion*
Hematopoietic Stem Cell Transplantation
Humans
In Situ Hybridization, Fluorescence
Male
Middle Aged
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / genetics*
Prognosis
Retrospective Studies
Survival Rate
Treatment Outcome